- Home
- SABR vs GHRS Comparison
SABR vs GHRS Comparison
Compare SABR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABR
- GHRS
- Stock Information
- Founded
- SABR 2006
- GHRS 2018
- Country
- SABR United States
- GHRS Ireland
- Employees
- SABR N/A
- GHRS N/A
- Industry
- SABR Computer Software: Programming Data Processing
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- SABR Technology
- GHRS Health Care
- Exchange
- SABR Nasdaq
- GHRS Nasdaq
- Market Cap
- SABR 1.2B
- GHRS 960.2M
- IPO Year
- SABR 2014
- GHRS 2021
- Fundamental
- Price
- SABR $3.27
- GHRS $14.24
- Analyst Decision
- SABR Hold
- GHRS Strong Buy
- Analyst Count
- SABR 5
- GHRS 8
- Target Price
- SABR $4.12
- GHRS $30.63
- AVG Volume (30 Days)
- SABR 4.7M
- GHRS 195.4K
- Earning Date
- SABR 08-07-2025
- GHRS 09-02-2025
- Dividend Yield
- SABR N/A
- GHRS N/A
- EPS Growth
- SABR N/A
- GHRS N/A
- EPS
- SABR N/A
- GHRS N/A
- Revenue
- SABR $3,023,296,000.00
- GHRS N/A
- Revenue This Year
- SABR $2.99
- GHRS N/A
- Revenue Next Year
- SABR $3.59
- GHRS N/A
- P/E Ratio
- SABR N/A
- GHRS N/A
- Revenue Growth
- SABR 2.56
- GHRS N/A
- 52 Week Low
- SABR $1.93
- GHRS $6.00
- 52 Week High
- SABR $4.63
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- SABR 60.55
- GHRS 47.01
- Support Level
- SABR $2.95
- GHRS $15.25
- Resistance Level
- SABR $3.21
- GHRS $19.51
- Average True Range (ATR)
- SABR 0.15
- GHRS 1.51
- MACD
- SABR -0.02
- GHRS -0.05
- Stochastic Oscillator
- SABR 56.14
- GHRS 21.34
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company announced a planned sale of its growing hotel IT solutions division (9% of revenue) to TPG for $960 million in net proceeds, which is scheduled to close in late 2025. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.